Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 5/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.42 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | KRAS | P01116 | 3/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14745358 | 0.89 | NR1H2 (0.51) | BACE1NR1H2USP30ESR2KRAS | |
| SCHEMBL6715677 | 0.84 | HTR2A (0.53) | NR1H2ESR2SIGMAR1CHRM2CHRM4 | |
| SCHEMBL18154550 | 0.81 | MCL1 (0.41) | SIGMAR1LMNANPC1MAPTRAB9A | |
| SCHEMBL16140212 | 0.80 | NR1H2 (0.51) | BACE1NR1H2USP30ESR2KRAS | |
| SCHEMBL31573849 | 0.78 | ESR2 (0.42) | NR1H2ESR2LMNACHRM2CHRM4 | |
| SCHEMBL30139011 | 0.77 | BACE1 (0.45) | BACE1NR1H2USP30ESR2KRAS | |
| SCHEMBL23726934 | 0.75 | NR1H2 (0.51) | NR1H2ESR2SIGMAR1MEN1KMT2A | |
| SCHEMBL1263942 | 0.75 | ESR2 (0.61) | BACE1NR1H2USP30ESR2LMNA | |
| SCHEMBL4055137 | 0.74 | NR1H2 (0.56) | NR1H2ESR2SIGMAR1LMNAMEN1 | |
| SCHEMBL9968767 | 0.74 | NR1H2 (0.44) | BACE1NR1H2USP30ESR2KRAS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3286193-A1 | INDOLE DERIVATIVES | Richter Gedeon Nyrt. (HU) | 2018-02-28 | — | — | EP | claimed |
| WO-2016166684-A1 | INDOLE DERIVATIVES | RICHTER GEDEON NYRT. (HU) | 2016-10-20 | — | — | WO | claimed |
| WO-2025094152-A1 | 18F AND11C RADIOLABELED MCHR1 PET LIGANDS | RICHTER GEDEON NYRT. (HU) | 2025-05-08 | — | — | WO | disclosed |
| EP-3286193-B1 | INDOLE DERIVATIVES | RICHTER GEDEON NYRT (HU) | 2020-05-27 | — | — | EP | disclosed |
| US-10329296-B2 | Indole derivatives | RICHTER GEDEON NYRT. (HU) | 2019-06-25 | — | — | US | disclosed |
| US-20180093989-A1 | INDOLE DERIVATIVES | RICHTER GEDEON NYRT. (HU) | 2018-04-05 | — | — | US | disclosed |
| EP-3286193-A1 | INDOLE DERIVATIVES | Richter Gedeon Nyrt. (HU) | 2018-02-28 | — | — | EP | disclosed |
| WO-2016166684-A1 | INDOLE DERIVATIVES | RICHTER GEDEON NYRT. (HU) | 2016-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10329296-B2 | Indole derivatives | TPH1, MCHR1, MC1R | BACE1 1894/4885NR1H2 497/4885USP30 3474/4885 |
| US-20180093989-A1 | INDOLE DERIVATIVES | MC1R, MCHR1, TPH1 | BACE1 2046/4885NR1H2 531/4885USP30 3709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.